# Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders

> **NCT04295681** · PHASE3 · COMPLETED · sponsor: **Materia Medica Holding** · enrollment: 246 (actual)

## Conditions studied

- Cognitive Disorders

## Interventions

- **DRUG:** MMH-MAP
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04295681
- **Lead sponsor:** Materia Medica Holding
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-12
- **Primary completion:** 2023-02-07
- **Final completion:** 2023-02-07
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04295681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04295681, "Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04295681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*